Grifols | GRFS - Debt

Stock Price
9.07
Daily Change
0 0%
Monthly
-1.41%
Yearly
22.90%
Q1 Forecast
9.14

Grifols reported EUR9.23B in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Arca Biopharma USD 0 0 Mar/2025
aTyr Pharma USD 1.84M 8K Sep/2025
Bio Path USD 261K 261K Mar/2025
Brainstorm Cell Therapeutics USD 1.2M 1.2M Mar/2025
Capricor Therapeutics USD 3.38M 0 Mar/2025
Cara Therapeutics USD 0 0 Mar/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Grifols EUR 9.23B 626.05M Dec/2024
Immunic USD 0 0 Jun/2024
Infinity Pharmaceuticals USD 0 0 Jun/2022
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 0 0 Jun/2022
Sangamo BioSciences USD 0 0 Jun/2022
TherapeuticsMD USD 93.6M 2.82M Sep/2022